Cartesian Therapeutics, Inc. 8-K Filing

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind
• $40,000 — ch provides for (i) annual retainers of $40,000 for his Board service and $7,500 for hi
• $7,500 — rs of $40,000 for his Board service and $7,500 for his Science and Technology Committe
• $8.29 — e Option has an exercise price equal to $8.29 per share, the fair market value of a s

Filing Documents

• rnac-20251216.htm (8-K) — 37KB
• codeofethicsandbusinesscon.htm (EX-14.1) — 77KB
• pressreleaseofcartesianthe.htm (EX-99.1) — 11KB
• cartesian_logoa.jpg (GRAPHIC) — 1239KB
• 0001453687-25-000140.txt ( ) — 1902KB
• rnac-20251216.xsd (EX-101.SCH) — 2KB
• rnac-20251216_lab.xml (EX-101.LAB) — 21KB
• rnac-20251216_pre.xml (EX-101.PRE) — 12KB
• rnac-20251216_htm.xml (XML) — 3KB

05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics

Item 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics. On December 16, 2025, the Board adopted an updated version of the Cartesian Therapeutics, Inc. Code of Business Conduct and Ethics (the "Code"), effective as of such date. The Code supersedes and replaces the Company's prior Code of Business Conduct and Ethics (the "Prior Code"). The Code applies to all directors, officers and employees of the Company and its subsidiaries and is intended to enhance understanding of the Company's standards of ethical business practices and promote awareness of ethical issues that may be encountered in carrying out a director's, officer's or employee's responsibilities. In addition, the Code is intended to constitute the Company's "code of ethics" within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and the rules and regulations of the Securities and Exchange Commission thereunder. Among other things, the Code: updates and clarifies the Company's requirements regarding the protection and proper use of Company assets and information, including requirements applicable to employees who use personal mobile phones, tablets, computers or other personal devices for Company business (bring-your-own-device or "BYOD"), including compliance with Company BYOD and information security policies and the Company's ability, to the extent permitted by law, to access, preserve, or remotely remove Company data from such devices; and makes various other updates, including clarifying, ministerial and conforming changes. The adoption of the Code did not result in any explicit or implicit waiver of any provision of the Prior Code. The foregoing description of the Code does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Code, a copy of which is filed as Exhibit 14.1 to this Current Report on Form 8-K and is incorporated herein by reference.

02 Regulation FD Disclosure

Item 7.02 Regulation FD Disclosure. On December 18, the Company issued a press release announcing the appointment of Dr. Bot to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor, shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 14.1 Cartesian Therapeutics, Inc. Code of Business Conduct and Ethics 99.1 Press Release of Cartesian Therapeutics, Inc., dated December 18, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: December 18, 2025 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR